No Data
No Data
Boji Medical Technology (300404.SZ): Xinglin Traditional Chinese Medicine's "CRA (raw materials)" and "CRA tablets (formulation)" have received drug clinical trial approval notifications.
Boji Medical Technology (300404.SZ) announced on August 9 that its wholly-owned subsidiary Xinglin Traditional Chinese Medicine Technology (Guangzhou) Co., Ltd. (hereinafter referred to as "Xinglin Traditional Chinese Medicine")'s "CRA (raw material)" and "CRA tablets (formulation)" have obtained the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration. The indications for "CRA (raw material)" and "CRA tablets (formulation)" are chronic heart failure. CRA is a monomeric compound extracted and purified from a single medicinal plant. Experimental studies have proven its definite curative effect on chronic heart failure. This drug belongs to traditional Chinese medicine.
Boji Medical Technology (300404.SZ): Subsidiary plans to participate in the investment of DaoYuan Angel Private Equity Fund.
On August 5th, Gelonhui reports that Boji Medical Technology (300404.SZ) announced that its wholly-owned subsidiary Guangdong Guangji Investment Co., Ltd. signed a partnership agreement on the angel (Jiaxing) equity investment enterprise (limited partnership) with Dao Yuan Capital Management (Beijing) Co., Ltd., Zhang Li Hanhua and Wang Hongyan. Guangji Investment participated in the investment of Dao Yuan Angel (Jiaxing) Equity Investment Enterprise (Limited Partnership) (referred to as the "Partnership Enterprise" or "Dao Yuan Angel Equity Investment Fund") as a limited partner. The total capital scale of this partnership enterprise is RMB 120 million yuan, and Guangji Investment invests 10 million yuan with its own funds.
Boji medical technology (300404.SZ): Not currently involved in DRG/DIP fields.
On July 29, Gelunhui reported that Boji Medical Technology (300404.SZ) stated on the investor interaction platform that the company is a professional CRO service provider mainly providing pharmaceutical outsourcing services to pharmaceutical companies and does not currently involve DRG/DIP fields.
A-share Lightning protection on July 15 | Tailin Bio: Gao De Investment intends to reduce its shareholding by no more than 1.67%; Chipbond Technology: expects to lose 0.439 billion yuan in the first half of the year.
Boji Medical Technology's controlling shareholder, the concerted action person, intends to reduce its shareholding by no more than 1.5%. Tailin Bio's shareholder, Gaode Investment, intends to reduce its shareholding by no more than 1.67%. Xilinx expects to lose 0.439 billion yuan in the first half of the year. Greentown Technology stated that the U.S. Commerce Department has initiated an anti-dumping and countervailing investigation into certain low-speed vehicles imported from China.
Boji Medical Technology (300404.SZ): Received government subsidies of 2.89 million yuan.
Boji Medical Technology (stock code 300404) announced on July 3 that its wholly-owned subsidiary, Shenzhen Brightgene Bio-Medical Technology Co., Ltd., has received government subsidy funds related to revenue of 2,890,000.00 yuan recently, accounting for 11.87% of the net income attributable to shareholders of the listed company in the last audited accounting year.
As Boji Medical TechnologyLtd (SZSE:300404) Jumps 16% This Past Week, Investors May Now Be Noticing the Company's Five-year Earnings Growth
No Data